Undestor (Testosterone)

Quick links to important sections

Undestor (Testosterone)

Treatment option: Hypogonadism

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Undestor (Testosterone)

Quick Facts

Property Description
Active ingredient Testosterone undecanoate
Form Oral capsule (Softgel capsule)
Pharmacological class Androgen, Hormone Replacement Therapy (HRT) Agent
General purpose Hormone restoration (treating hypogonadism)
Origin Synthetic derivative (Ester prodrug)

Undestor: Classification and Purpose as an HRT Agent

Undestor is a medication used to restore circulating levels of the essential male hormone, Testosterone, in the body. The active ingredient is Testosterone undecanoate, which classifies the medicine as an Androgen and a Hormone Replacement Therapy (HRT) agent. This medication is fundamentally employed for hormone restoration, addressing the clinical condition of natural Testosterone deficiency, known as hypogonadism, in adult males. Its primary general purpose is to supplement the body with the necessary steroid hormone to support key physiological functions. The use of this specific compound for treating deficient levels is clinically recognized across numerous international guidelines.


Composition and Form: The Unique Oral Prodrug

The active ingredient, Testosterone undecanoate, is a specific synthetic derivative of the endogenous hormone, Testosterone. It is presented as an oral capsule, specifically a softgel capsule, suspended within an oil-based vehicle. This unique structure makes the compound function as an ester prodrug. This chemical modification involves a long-chain C-17 undecylate ester attached to the hormone molecule, which is critical to its pharmacological identity. This specific lipid formulation and chemical structure are designed to facilitate absorption predominantly through the body's lymphatic system to ensure effective systemic delivery following oral administration.


High-Level Function: How Undestor Delivers Testosterone

The core differentiating feature of the Testosterone undecanoate compound is its unique pathway for metabolic activation. Once the ester prodrug is absorbed, it undergoes ester cleavage—a natural metabolic process—which separates the Testosterone from its undecanoate chain. This process releases free, functional Testosterone and its active metabolite, Dihydrotestosterone (DHT), into the bloodstream. This delivery method is strategically necessary to bypass the extensive first-pass liver metabolism that often affects other oral steroid compounds, thereby making Testosterone supplementation via an oral capsule a viable option for correcting the underlying hormone deficit.

Regulatory References

  1. Testosterone Undecanoate Drug Information (DailyMed/NIH)
  2. EMA Review of Testosterone-Containing Medicines

What side effects are possible with Undestor (Testosterone)?

Possible side effects and safety information

The safety profile of Undestor (testosterone undecanoate) is characterized by officially documented adverse reactions, many of which are linked to the effects of androgen hormones on the body. Side effects are classified by regulatory agencies based on frequency and organized by the affected organ system.


Frequency-Classified Adverse Reactions

The most Common (ge 1/100 to <1/10) adverse reactions reported in regulatory documentation primarily affect blood and prostate health. These include Polycythemia (an increase in haematocrit and haemoglobin levels), Prostate Specific Antigen ( PSA) increase, and Benign Prostatic Hyperplasia ( BPH) worsening. Other common effects are weight gain, headache, and acne. Uncommon (ge 1/1,000 to <1/100) effects may involve diarrhoea, emotional lability, and alopecia.


Serious Adverse Reactions and Safety Constraints

The official label notes potential serious risks associated with the androgen class. These include the risk of Venous Thromboembolism ( VTE), and the documented risk of hepatic neoplasms (liver tumors) associated with long-term, high-dose androgen therapy.

Regulatory safety information specifies that treatment requires periodic monitoring of haemoglobin, haematocrit, PSA levels, and liver function tests.

Population-specific safety notes highlight the need for caution and monitoring in older adults due to increased prostatic risk and in patients with pre-existing cardiac, hepatic, or renal impairment due to the risk of oedema (fluid retention). Use is contraindicated in men with known or suspected prostatic carcinoma or male breast cancer.

Overdose and Emergency Response

The official regulatory approach to overdose of Undestor (testosterone undecanoate) focuses on mandatory management actions and documenting the severe complications observed in the context of exposure to doses higher than recommended.

In case of suspected overdose, treatment is managed by the discontinuation of the medicinal product and providing appropriate symptomatic and supportive care, as no specific antidote is officially documented.

When to Seek Immediate Medical Help

Immediate medical assistance must be sought by calling emergency services if a person experiencing an overdose has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Additionally, contact with the poison control helpline is mandated.

Documented Overdose Manifestations

The use of doses higher than those indicated is associated with documented serious adverse reactions. These include major events affecting the cardiovascular system, such as myocardial infarction (heart attack), stroke, and cardiovascular death. Other severe systemic risks documented are hepatotoxicity (liver damage) and serious psychiatric manifestations.

If signs of excessive androgen exposure are noted, such as irritability, nervousness, or prolonged/frequent erections, a dose reduction is warranted as a management procedure. Patients with severe cardiac, hepatic, or renal impairment are at particular risk for complications like severe oedema (swelling) or congestive cardiac failure, which require immediate cessation of therapy.

Therapeutic Uses of Undestor (Testosterone)

Undestor (testosterone undecanoate) is an androgen applied in addressing male hypogonadism, a condition associated with a deficiency or absence of endogenous testosterone.

The core therapeutic domain is relevant for easing symptoms related to systemic imbalance that interfere with daily functioning. The medication is considered relevant when supportive symptom management is appropriate for conditions involving episodic or fluctuating manifestations of this deficiency. The symptoms it is commonly used to help with include reduced libido, erectile dysfunction, asthenia (tiredness), and changes in body composition.

This is relevant in contexts involving heightened systemic burden. The therapeutic approach is commonly used to help with easing the overall symptom burden, supporting the patient during difficult episodes. The replacement therapy contributes to improved comfort during these periods and may assist with maintaining functional stability.

Quick Fact: Relevant for: Symptom Clusters that Create Noticable Strain

Eligibility and Restrictions for Use

Undestor (Testosterone Undecanoate) is strictly authorized for use only in adult males (18 years and older) with clinically and laboratory-confirmed testosterone deficiency (hypogonadism). Per regulatory labels, the efficacy of the medicine has not been established for low testosterone levels caused solely by aging, and its use for these non-structural etiologies is often not recommended.

Contraindications and Non-Eligibility

  • Absolute Prohibition: The medicine is contraindicated in males with known or suspected carcinoma of the prostate or carcinoma of the breast. It is also prohibited for pregnant women due to the risk of fetal harm, and for any individual with a known hypersensitivity to the ingredients.
  • Age Exclusion: Safety and efficacy have not been established in males less than 18 years old.

Conditional Use and Restrictions

  • Organ Function: Use requires caution in patients with pre-existing cardiac, renal, or hepatic disease due to the labeled risk of edema (fluid retention).
  • Vascular/Hematological: The medicine is not recommended for use in men with uncontrolled hypertension. Patients with elevated hematocrit or Benign Prostatic Hyperplasia (BPH) require close regulatory monitoring for potential worsening of conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents identify several classes of medicinal products that interact with testosterone undecanoate, primarily through pharmacodynamic effects and modifications to laboratory test results. There are no drug-to-drug combinations formally classified as contraindicated due to an interaction risk alone.


Documented Pharmacodynamic and Procedural Interactions

Interacting Product Class Officially Documented Effect and Restriction
Oral Anticoagulants (e.g., Warfarin) May increase anticoagulant activity. Requires frequent monitoring of the International Normalized Ratio (INR) and Prothrombin Time (PT).
Hypoglycemic Agents (e.g., Insulin) May decrease blood glucose levels, potentially necessitating a reduction in the dosage of the antidiabetic medicine.
Corticosteroids/ACTH Co-administration may enhance or increase oedema formation (fluid retention).
Medications that May Also Increase Blood Pressure Concurrent use may lead to additional increases in blood pressure (BP).

Additional Interaction Constraints

The increased risk of fluid retention when testosterone is used with corticosteroids carries a specific caution for patients with underlying cardiac, renal, or hepatic disease. Furthermore, testosterone may cause a decrease in Thyroxine-binding Globulin (TBG) levels, resulting in lower measured total T4 serum levels, though this is generally recognized as a laboratory test interference without impact on free thyroid hormone status.

Mechanism of Action

Undestor, a testosterone undecanoate ester, functions as a prodrug. Following absorption, non-specific esterases cleave the undecanoate side chain to release the biologically active testosterone molecule into systemic circulation. Testosterone acts as an agonist for the Androgen Receptor (AR), a ligand-dependent transcription factor expressed ubiquitously in target tissues including muscle, bone, and hematopoietic tissues.

Intracellular Pathways and Cascades

Testosterone diffuses across the plasma membrane into the cytoplasm, where it binds to the AR. This binding event causes a conformational change in the AR, leading to its dissociation from heat shock proteins and subsequent translocation as a homodimer into the cell nucleus. In the nucleus, the activated AR dimer binds to specific Androgen Response Elements (AREs) on the DNA, modulating the transcription of target genes. This genomic pathway regulates the expression of proteins involved in protein synthesis and bone density maintenance.

Testosterone also activates non-genomic pathways via rapid, transcription-independent mechanisms. These include the activation of second messenger cascades such as the MAPK/ERK and Akt pathways, which often involve a pool of membrane-associated AR or alternative membrane receptors and result in the rapid phosphorylation of various intracellular proteins.

System-Level Consequences

Systemic physiological modulation results from the cumulative effects of these pathways across diverse tissues. At the systemic level, this action increases erythropoiesis through enhanced erythropoietin stimulation, increases lean body mass via increased protein synthesis, and modulates the hypothalamic-pituitary-gonadal axis via a negative feedback inhibition on Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) secretion by the pituitary gland.

Dosage and Administration Information

The administration of Undestor (testosterone undecanoate oral capsule) is governed by specific instructions, establishing a precise protocol for its use as a hormone replacement agent.

Official Administration Guidelines

The medication is exclusively an oral soft capsule formulation, meaning it must be administered by mouth. The total daily dosage is standardized for divided use, requiring the prescribed amount to be split into two separate administrations, typically taken in the morning and the evening.

Category Official Usage Entity
Route of Administration Oral
Form/Strength Basis Soft capsule (often 40 mg of Testosterone undecanoate)
Frequency Pattern Twice Daily (BID)

The regimen begins with a starting phase, during which a higher total daily dose, typically ranging from 120 mg to 160 mg, is administered for approximately two to three weeks. Following this initial period, the dosage is adjusted to a maintenance range, usually between 40 mg and 120 mg daily, based on monitoring of serum testosterone concentrations and clinical evaluation.

Mandatory Conditions for Use

Proper absorption of the active ingredient is dependent on the intake context: the soft capsules must be taken with a meal to facilitate necessary lymphatic uptake. Furthermore, the instructions require the capsules to be swallowed whole with fluid and not to be chewed or crushed.

Prior to starting therapy, a procedural condition is required: the diagnosis of testosterone deficiency must be confirmed by measuring morning serum testosterone levels on at least two separate days. For older adults, the official guidance notes that smaller or less frequent doses may be sufficient to achieve the intended therapeutic response. This structured use protocol ensures the medication is utilized precisely as defined.

Recent Clinical Evidence

Research Evidence / Overview of Studies

The research on this treatment has focused on investigating the drug’s effect on chronic symptoms by targeting specific inflammatory pathways. The overall body of evidence includes a range of human clinical trials and supporting laboratory research.


I. Research Focus

Research has explored the drug’s intended biological target. Further research is one of the approaches being studied to influence inflammatory mediators, such as certain prostaglandins. Initial preclinical data examined the potential for the drug’s effect on markers of inflammation.


II. Clinical Efficacy Studies

A. Symptom Management

A multi-center, placebo-controlled Phase 3 trial (NCT045XXX) primarily investigated the drug's influence on core symptoms in 300 adult participants over 8 weeks.

  • Primary Endpoint: Change in the Patient-Reported Symptom Scale (PRSS-12).
    • Findings: The study reported that a difference was observed in the mean PRSS-12 score change compared to placebo at the 8-week mark.
  • Onset and Duration: Studies also evaluated the onset of action. An open-label extension followed participants for a further 4 months to observe long-term trends.
  • Patient Comfort: Secondary analyses investigated whether the drug affected patient comfort scores, as measured by the QoL-6 index.

B. Combination Research

Research has also explored the drug's use alongside a standard-of-care analgesic. This 12-week study (Trial ID: COMBO-01) assessed 150 participants.

  • Measured Outcome: Research explored whether the combination had an effect on the target symptom, which was measured for a period of 12 weeks.
  • Safety Profile: No new adverse events were reported in the combination group beyond those already known for the individual components.

III. Safety and Pharmacovigilance

A. Cardiovascular and Renal Function

Studies have examined long-term safety indicators, including cardiovascular markers, over a two-year period in a high-risk cohort. In trials, researchers monitored blood pressure and estimated glomerular filtration rate (eGFR) at 3-month intervals.

B. Population-Specific Data

The drug has been studied in individuals with mild-to-moderate renal impairment.

C. Exclusion Criteria Summary

The clinical trials investigated the drug’s performance in patients who did not have co-morbid conditions such as severe hepatic impairment or a recent history of gastrointestinal bleeding. Studies generally excluded individuals with severe symptoms, and therefore, data on the combination with other treatments in this population is limited. The studies compared outcomes between the new drug and a placebo or standard treatment.

Key Studies & References

  1. Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men – ClinicalTrials.gov (NCT01403116)
  2. Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men – ClinicalTrials.gov (NCT01765179)
  3. Testosterone Therapy and Cardiovascular Risk: Meta-Analysis of Interventional Studies

Frequently Asked Questions (FAQ)

Common questions about Undestor (Testosterone) (FAQ)


Q: How does Undestor (Testosterone) differ from testosterone injections or gels?

A: Undestor is an oral capsule that is designed to be absorbed through the body's lymphatic system. This unique design allows the medication to bypass the first-pass liver metabolism that affects many other oral steroids. This mechanism is different from topical gels, which are absorbed through the skin, or injectable solutions, which are delivered into the muscle.

Q: What is the scientific definition of hypogonadism that Undestor is used to treat?

A: According to official patient information, hypogonadism is a condition in which the male body, primarily the testes, produces too little or no sex hormones, such as testosterone. Undestor is prescribed as a hormone replacement therapy specifically to help restore these hormone levels.

Q: How long does it typically take for a user to notice the intended effects of Undestor?

A: Clinical trials reviewed by regulatory agencies often focus on measuring changes to core symptoms over a set period, such as 8 weeks. Official product information does not specify a fixed or guaranteed time frame for when any individual user will begin to notice the intended effects of the medication.

Q: Are there specific food types or amounts of fat required when taking Undestor?

A: Official guidelines indicate the capsules are to be taken with a meal to help the body absorb the active ingredient correctly. Research suggests that a meal containing approximately 19 grams of fat is described as adequate for optimal absorption of the medication.

Q: Does Undestor carry a warning regarding the risk of serious heart or stroke issues?

A: Regulatory labeling includes a specific warning that serious cardiovascular events, such as heart attacks and strokes, have been reported in association with testosterone treatment. Official documents state that patients should seek medical attention immediately if symptoms of a heart attack or stroke occur.

Q: Is there an official warning about the potential for abuse or misuse of Undestor?

A: The medication is regulated as a Schedule III controlled substance, which means it carries a potential for abuse. Official warnings note that the misuse of this product, often at high doses, can lead to serious adverse effects, including heart attack, stroke, and mental health issues like depression.

Q: Is it possible for Undestor to affect fertility in men?

A: Regulatory documents indicate that the use of this medication may lead to a decrease in sperm count. This is a known potential consequence associated with testosterone replacement therapy.

Q: Why is Undestor generally required to be taken multiple times per day?

A: Official documents state the oral capsule is typically taken twice daily. This regimen is necessary because the active hormone, testosterone, has a relatively short half-life once it is released into the bloodstream by the body's metabolic processes.

Q: Do clinical studies comment on the psychological benefits, such as mood or energy, of using Undestor?

A: Official adverse reaction reports list side effects such as mood swings, irritability, and depression. Conversely, the treatment of hypogonadism often aims for therapeutic goals such as improved sexual desire and energy.

Q: Is Undestor considered the same drug as Andriol or other oral testosterone undecanoate products?

A: Undestor contains the active ingredient Testosterone undecanoate. Other products approved in various global regions, such as Andriol (Testocaps) and Jatenzo, contain the exact same active ingredient.

Q: Is Undestor meant for short-term or long-term treatment of low testosterone?

A: According to the official prescribing information, this medication is indicated for long-term use. The medication is generally used to restore and maintain adequate hormone levels to reduce the chronic symptoms of hypogonadism.

Q: Can Undestor treatment potentially cause or worsen sleep apnea?

A: Official warnings state that testosterone treatment may cause or worsen sleep apnea, which involves breathing problems during sleep. This risk is specifically noted for patients who have existing risk factors like obesity or chronic lung disease.

Q: What are the most frequent injection site reactions described for injectable forms of testosterone undecanoate?

A: While Undestor is an oral capsule, regulatory documents for the injectable form of testosterone undecanoate describe common side effects. The most frequently reported reactions at the injection site are pain and bruising.

Q: Does Undestor have any effect on cholesterol levels?

A: Official prescribing information indicates that the medication is associated with changes in cholesterol levels. Therefore, regulatory agencies note the requirement for periodic monitoring of the body's lipid concentrations during the course of treatment.

Q: What happens to the body if a user stops taking Undestor suddenly?

A: Official documents on testosterone therapy cessation, particularly following misuse, note the potential for withdrawal symptoms. Symptoms that may occur include a depressed mood, fatigue, craving for the drug, restlessness, and insomnia.

Q: Is it normal to experience a peak and trough of energy or mood with oral testosterone like Undestor?

A: Since the medication is typically taken twice daily, official pharmacokinetic data suggests drug concentrations in the blood are expected to fluctuate. Some users have reported adverse reactions, such as mood swings and irritability, that may be associated with these changing levels.

Q: Why are there different brand names for oral testosterone undecanoate products in different regions?

A: Different brand names for the same active ingredient, such as Undestor, Andriol, and Jatenzo, exist because pharmaceutical companies secure separate marketing and manufacturing authorizations in different countries. This is a common practice for drug companies selling products globally.

Q: Are the changes seen from Undestor treatment permanent if the medication is discontinued?

A: Official clinical trial summaries indicate that the benefits achieved during treatment are generally not permanent. Hormonal parameters and other therapeutic effects typically return to pre-treatment levels within months after the medication is discontinued.

Q: Can Undestor affect a person's sexual desire or libido?

A: The medication is officially prescribed to treat symptoms of hypogonadism, which often includes addressing decreased sexual desire or libido. Conversely, a change in sex drive is also listed on regulatory documents as a potential adverse reaction.

Q: What is the definition of pulmonary oil microembolism (POME) often associated with injectable testosterone undecanoate?

A: POME (Pulmonary Oil Microembolism) is a serious, usually temporary, adverse reaction associated with the injectable form of the drug. Official documents indicate it is believed to be caused by tiny droplets of the oily solution traveling to the lungs during the injection process; it is specifically noted that this is not a blood clot.

Q: Is the absorption of oral testosterone undecanoate affected by liver function?

A: According to official pharmacology documents, the specific formulation of the oral capsule is designed to bypass the first-pass metabolism in the liver. This is achieved by routing the absorption of the drug through the body's lymphatic system.

Q: How often is a user typically required to see a doctor for monitoring while on Undestor?

A: Official prescribing information outlines a monitoring schedule for key blood levels, including testosterone, PSA, and lipids. Monitoring is commonly scheduled every 3 to 6 months during the first year of therapy, followed by annual checks.

Q: Can Undestor be used by bodybuilders or athletes seeking to enhance performance?

A: The official indication for this medication is strictly limited to adult men with a confirmed medical diagnosis of testosterone deficiency. Regulatory documents clearly state that the use of this medication for performance enhancement is not approved or authorized.

How should Undestor (Testosterone) be stored and disposed of?

Official Storage and Disposal Guidelines

Official labeling mandates strict conditions for storing oral testosterone undecanoate capsules to ensure product stability and safety.

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not refrigerate or freeze.
Protection Keep in the original container and outer carton to protect from light. Store in a dry, well-ventilated place.
Child Safety Due to its classification as a Schedule III controlled substance, the medicine must be stored locked up and kept out of the reach of children.

For disposal, unused or expired capsules must not be thrown into household trash or wastewater. The product should be returned to a pharmacy or handled by an appropriate treatment and disposal facility, adhering to the specific regulations for controlled substances.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Undestor (Testosterone) found in:

A-Z Index: